Person: DANE, FAYSAL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DANE
First Name
FAYSAL
Name
15 results
Search Results
Now showing 1 - 10 of 15
Publication Metadata only The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy(SPRINGER, 2012) ATASOY, BESTE MELEK; Atasoy, Beste M.; Yonal, Oya; Demirel, Birsen; Dane, Faysal; Yilmaz, Yusuf; Kalayci, Cem; Abacioglu, Ufuk; Imeryuz, NeseTo investigate the impact of early insertion of percutaneous endoscopic gastrostomy-tube on nutritional status and completeness of concurrent chemotherapy in locally advanced head and neck cancer patients treated with chemoradiotherapy. Twenty-three patients were enrolled into this prospective study. Gastrostomy-tube was inserted in patients before the initiation of chemoradiotherapy. There was not any significant change in nutritional parameters of patients that used their tube during treatment. Despite the grade 3 mucositis, the planned concurrent chemotherapy could be given in 70% of the patients. However, nine patients had weak compliance and their body weight (P = 0.01) and body mass index (P = 0.01) deteriorated in the first 4 weeks of chemoradiotherapy. The completeness of concurrent chemo-rate was 44% in these patients. Toxicity, requiring aggressive supportive care, may limit the chemotherapy part of curative concomitant chemoradiotherapy. By providing adequate enteral nutrition the insertion of gastrostomy-tube can increase the completeness rate of concurrent chemotherapy.Publication Metadata only Grad III anaplasti̇k gli̇al tümör tanili hastalarda radyoterapi̇yle eş zamanli adjuvan temozolami̇d sonuçlari tek merkez deneyi̇mi̇(2014-05-23) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; Sahibov E., Atasoy B. M., Şeker A., Özgen Z., Dane F., Ziyal M. İ., Abacıoğu U.Publication Metadata only Rektum kanseri̇ni̇n adjuvan tedavi̇si̇nde radyoterapi̇yle eş zamanli tegafur urasi̇l uft foli̇ni̇k asi̇t fa uygulamasi tolerabi̇li̇te değerlendi̇rmesi̇(2006-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; ATASOY B. M. , ABACIOĞLU U., ÖZGEN Z., DANE F., YUMUK P. F. , MAYADAĞLI A., TURHAL S., ŞENGÖZ K. M.Publication Metadata only Health-Related Quality of Life During Postoperative Chemoradiotherapy with Oral Uracil-Tegafur and Leucovorin in Rectal Cancer Patients(H G E UPDATE MEDICAL PUBLISHING S A, 2013) ATASOY, BESTE MELEK; Ozgen, Zerrin; Ozden, Sevgi; Dane, Faysal; Atasoy, Beste M.; Akgunt, Zuleyha; Yumuk, P. Fulden; Mayadagli, Alpaslan; Turhal, N. Serdar; Abacioglu, UfukBackground/Aims: The objective of this study was to report on the quality of life of locally advanced rectal cancer patients that were treated with uracil-tegafur (UFT)/leucovorin (LV)-based concurrent chemoradiotherapy. Methodology: Twenty-five patients were enrolled into this prospective study. Radiotherapy (50.4Gy) was given with concurrent UFT (300mg/m(2)/day) and LV (30mg/day). Turkish versions of EORTC-QLQC30 and EORTC QLQCR38 were applied at the beginning (HROoL-1) and at the end (HRQoL-2) of chemoradiotherapy. Paired samples t-test was used to compare the difference of means for each scale between HRQoL1 and HRQoL2 and p values <0.05 were considered statistically significant. Results: Study compliance was 80.6%. From baseline to the end of chemoradiotherapy, the mean scores of dyspnea (p=0.006) diarrhea (p=0.005) and micturition (p=0.005) increased significantly. Chemotherapy side effects also increased at the end of therapy (p=0.07). Seventy-six percent (76%) of male patients replied to questions related to sexual problems and functions, whereas no female patients replied. Conclusions: Although, diarrhea and micturition are the major problems, quality of life scores indicate that concurrent oral fluoropyrimidine-based chemoradiotherapy is a feasible treatment.Publication Metadata only Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer(TURKISH SOC GASTROENTEROLOGY, 2011) ATASOY, BESTE MELEK; Atasoy, Beste Melek; Dane, Faysal; Kefeli, Aysegul Ucuncu; Caglar, Hale; Cingi, Asim; Turhal, Nazim Serdar; Abacioglu, Ufuk; Yegen, CumhurBackground/aims: This study aimed to demonstrate the efficacy and tolerability of low-dose weekly gemcitabine as a radiosensitizer in unresectable pancreatic cancer patients treated with chemoradiotherapy. Methods: Twenty-four histologically confirmed pancreatic carcinoma patients (female/male: 10/14, median age: 60) were evaluated. Seven (29%) patients received gemcitabine either as a single agent or in combination prior to chemoradiotherapy. Concurrent 75 mg/m(2) gemcitabine was infused weekly. Radiotherapy was delivered to the primary tumor and positive lymphatics with 3D-conformal radiotherapy to a total dose of 4500 cGy. Local progression-free survival, distant metastasis-free survival and overall survival were evaluated by Kaplan-Meier method. Results: Median follow-up was 36 weeks. Median local progression-free survival, distant metastasis-free survival and overall survival were 22 weeks (95% confidence interval [CI]: 5-59 weeks), 19 weeks (95%CI: 6.9-31 weeks) and 36 weeks (95%CI: 28-43 weeks), respectively. All patients completed radiotherapy as scheduled. Concurrent gemcitabine was given fully in 58.3% of patients. Gemcitabine was terminated in four (16.6%) patients due to grade 3 neutropenia (n=1), grade 3 nausea/vomiting (n=2) or patient's reluctance (n=1). Patients with local response and stable disease to chemoradiotherapy revealed a median survival of 39 weeks (95%CI: 30-47.9 weeks) compared to 36 weeks (95%CI: 9.7-62.2 weeks) in patients with locally progressive disease (p=0.52). Pain was improved in 50% of patients. Conclusions: Weekly low-dose radiosensitizing gemcitabine is effective and safe in unresectable pancreatic cancer patients.Publication Metadata only Kanser tanisi alan hastalarda poli̇kli̇ni̇k şartlarinda üç farkli test İle nütri̇syonel durum değerlendi̇rmesi̇(2012-04-19) ATASOY, BESTE MELEK; ÖZGEN, ZERRİN; DANE, FAYSAL; YUMUK, PERRAN FULDEN; Atasoy B. M., Aygör H. A., Günaydın D., Özlen T., İbrahimov R., Özgen Z., Dane F., Yumuk P. F.Publication Open Access Radiation-induced oxidative injury of the ileum and colon is alleviated by glucagon-like peptide-1 and -2(ELSEVIER SCIENCE BV, 2015-04) ATASOY, BESTE MELEK; Deniz, Mustafa; Atasoy, Beste M.; Dane, Faysal; Can, Guray; Erzik, Can; Cetinel, Sule; Yegen, Berrak C.Purpose: The present study was conducted to characterize the possible therapeutic effects of glucagon-like peptide (GLP)-1 and GLP-2 against oxidative damage in the ileum and colon of irradiated rats. Methods and materials: Sprague-Dawley rats of both sexes received either a single dose of GLP-1 (0.1 nmol/kg, intraperitoneally, ip; n = 6) 10 min before abdominal irradiation (IR) or two consecutive doses of GLP-2 (7 nmol/kg, ip; n = 6) at 30 and 10 min before IR, while another group was administered vehicle (n = 6) 10 min before IR. Control rats (n = 6) received vehicle treatment without IR. On the fourth day of IR, samples from ileum and colon were removed for histological analysis, for the determination of myeloperoxidase (MPO) activity, malondialdehyde (MDA) and glutathione (GSH) levels, as well as DNA fragmentation ratio, an index of apoptosis. Results: IR-induced oxidative injury in the colonic tissue of vehicle-treated rats, evidenced by elevated MDA levels and MPO activity, as well as depleted colonic GSH levels, was reversed by GLP-2, while GLP-1 reduced IR-induced elevations in colonic MDA levels. IR-induced injury with elevated ileal MDA levels was reduced by GLP-1, while replenishment in GSH was observed in GLP-2-treated rats. Conclusion: Current findings suggest that GLP-1 and GLP-2 appear to have protective roles in the irradiation-induced oxidative damage of the gut by inhibiting neutrophil infiltration and subsequent activation of inflammatory mediators that induce lipid peroxidation. Copyright (C) 2015, The Egyptian Society of Radiation Sciences and Applications. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.Publication Open Access Functional and clinical evaluation of renal injury in patients treated with adjuvant chemoradiotherapy for gastric cancer: Low dose and comorbidity considerations(ELSEVIER SCIENCE BV, 2016-01) ATASOY, BESTE MELEK; Ibrahimov, Roman; Atasoy, Beste M.; Dede, Fuat; Arikan, Hakki; Ozen, Zeynep; Ozgen, Zerrin; Dane, Faysal; Abacioglu, UfukAim: To analyze the dosimetric factors affecting long-term renal function in patients with gastric cancer following postoperative radiotherapy with concomitant chemotherapy to the upper abdomen. Methods: Between January 2005 and July 2010, 13 patients treated with three-dimensional conformal radiotherapy and concurrent fluorouracil-based chemotherapy (CRT) were included in this analysis. After a median follow-up of 55 months, creatinine, glomerular filtration rate (GFR), total kidney and left kidney volumes, before and after CRT and mercaptoacetyltriglycine (MAG3) scintigraphy, were used to evaluate the renal function and were correlated with the dosimetrics data. Results: Significant correlations were found in the loss of left kidney volume and V35 (20.6%) (p = 0.035) and V40 (15.7%) (p = 0.031) and in the loss of relative functional contribution of the main kidney and V35 Gy (p = 0.027) and V40 Gy (p = 0.019). In patients with a slightly low basal GFR (n = 6), the relative functional contribution of the left kidney significantly decreased, regardless of the dosage. Conclusion: Functional renal impairment without any clinical signs or symptoms can be observed in low doses after radiotherapy. Careful treatment planning and a detailed evaluation of the functional renal capacity before treatment may help to reduce late renal toxicity. Copyright (C) 2015, The Egyptian Society of Radiation Sciences and Applications. Production and hosting by Elsevier B.V.Publication Metadata only Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience(SAGE PUBLICATIONS LTD, 2021) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M.; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P. FuldenPurpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17-77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1-68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.Publication Metadata only Prophylactic feeding with immune-enhanced diet ameliorates chemoradiation-induced gastrointestinal injury in rats(TAYLOR & FRANCIS LTD, 2010) ATASOY, BESTE MELEK; Atasoy, Beste M.; Deniz, Mustafa; Dane, Faysal; Ozen, Zeynep; Turan, Pinar; Ercan, Feriha; Cerikcioglu, Nilguen; Aral, Cenk; Akgun, Zueleyha; Abacioglu, Ufuk; Yegen, Berrak C.Materials and methods: Forty-eight Sprague-Dawley rats were divided into control (C, n = 6), irradiation (IR, n = 14), fluoropyrimidine (5-FU, n = 14)-treated, IR + 5-FU (n = 14)-treated groups. Half of each irradiated and/or 5-FU-treated groups were previously fed with IED containing arginine, omega-3-fatty acids and RNA fragments, while the other half were fed a standard rat diet (SD) for eight days before the induction of IR or injection of 5-FU. In IR groups, whole abdominal irradiation (11 Gy) was performed with 6 MV photons. In the 5-FU groups, fluoropyrimidine (100 mg/kg) was administered intraperitoneally 30 min prior to irradiation. All animals were sacrificed on the 4th day of IR or 5-FU injection. Results: Bacterial colony counts in the ceca and mesenteric lymph nodes of IED-fed rats, which have received either 5-FU and/or irradiation were significantly lower than the corresponding SD-fed groups. Morphometric results revealed that gastric, ileal and colonic injuries were less in IED-treated IR or IR + 5-FU + IED groups, as compared to SD-fed groups. However, IED did not alter DNA fragmentation ratios. Conclusion: Prophylactic feeding of IED has a protective effect on chemoradiation-induced gastrointestinal injury, which appears to involve the eradication of bacterial overgrowth.